Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders
Authors
Keywords
-
Journal
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Volume 187, Issue 2, Pages 304-315
Publisher
Wiley
Online
2016-11-17
DOI
10.1111/cei.12890
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study
- (2016) Michael Loschi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH
- (2016) Sandra Habbig et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab
- (2016) Magdalena Riedl et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015
- (2015) Marina Noris et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Response: Maternal and cord C5a in response to eculizumab
- (2015) R. M. Burwick et al. BLOOD
- Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo
- (2015) E. B. Volokhina et al. BLOOD
- Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS
- (2015) R. Cofiell et al. BLOOD
- Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission
- (2015) E. B. Volokhina et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Applying complement therapeutics to rare diseases
- (2015) Edimara S. Reis et al. CLINICAL IMMUNOLOGY
- Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome
- (2015) Elena B. Volokhina et al. CLINICAL IMMUNOLOGY
- Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule
- (2015) Philippe Gatault et al. mAbs
- The role of complement in C3 glomerulopathy
- (2015) Peter F. Zipfel et al. MOLECULAR IMMUNOLOGY
- A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab
- (2015) Gesa Schalk et al. PEDIATRIC NEPHROLOGY
- An international consensus approach to the management of atypical hemolytic uremic syndrome in children
- (2015) Chantal Loirat et al. PEDIATRIC NEPHROLOGY
- Case Report: Benefits and Challenges of Long-term Eculizumab in Atypical Hemolytic Uremic Syndrome
- (2015) N. Cullinan et al. PEDIATRICS
- A national specialized service in England for atypical haemolytic uraemic syndrome—the first year’s experience
- (2015) N.S. Sheerin et al. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
- Eculizumab in the Treatment of Membranoproliferative Glomerulonephritis
- (2015) Andrew S. Bomback NEPHRON CLINICAL PRACTICE
- Discontinuation of Eculizumab Maintenance Treatment for Atypical Hemolytic Uremic Syndrome: A Report of 10 Cases
- (2014) Gianluigi Ardissino et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab
- (2014) R. Peffault de Latour et al. BLOOD
- Eculizumab fails to inhibit generation of C5a in vivo
- (2014) R. M. Burwick et al. BLOOD
- Dynamics of complement activation in aHUS and how to monitor eculizumab therapy
- (2014) M. Noris et al. BLOOD
- Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis
- (2014) C. Wehling et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome
- (2014) M. Cugno et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Genetic Variants in C5 and Poor Response to Eculizumab
- (2014) Jun-ichi Nishimura et al. NEW ENGLAND JOURNAL OF MEDICINE
- Eculizumab hepatotoxicity in pediatric aHUS
- (2014) Wesley Hayes et al. PEDIATRIC NEPHROLOGY
- Antibody-mediated rejection despite inhibition of terminal complement
- (2014) Andrew Bentall et al. TRANSPLANT INTERNATIONAL
- Targeting the complement system in systemic lupus erythematosus and other diseases
- (2013) Maria-Louise Barilla-LaBarca et al. CLINICAL IMMUNOLOGY
- The use of eculizumab in renal transplantation
- (2013) A. Nicholas R. Barnett et al. CLINICAL TRANSPLANTATION
- Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases
- (2013) Carla M. Nester et al. CURRENT OPINION IN PEDIATRICS
- Atypical hemolytic uremic syndrome: From the rediscovery of complement to targeted therapy
- (2013) Fadi Fakhouri et al. European Journal of Internal Medicine
- Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria
- (2013) T. Rondelli et al. HAEMATOLOGICA
- Complement therapy in atypical haemolytic uraemic syndrome (aHUS)
- (2013) Edwin K.S. Wong et al. MOLECULAR IMMUNOLOGY
- Eculizumab and recurrent C3 glomerulonephritis
- (2013) Sevgi Gurkan et al. PEDIATRIC NEPHROLOGY
- Eculizumab for Salvage Treatment of Refractory Antibody-Mediated Rejection in Kidney Transplant Patients: Case Reports
- (2013) B. Kocak et al. TRANSPLANTATION PROCEEDINGS
- Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation
- (2012) Ryan Carr et al. ANNALS OF HEMATOLOGY
- Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway
- (2012) M. J. Krisinger et al. BLOOD
- Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis
- (2012) A. S. Bomback et al. Clinical Journal of the American Society of Nephrology
- Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria
- (2012) Amy E. DeZern et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- A time for reappraisal of “atypical” hemolytic uremic syndrome: should all patients be treated the same?
- (2012) Rebecca L. Ruebner et al. EUROPEAN JOURNAL OF PEDIATRICS
- Pathology after Eculizumab in Dense Deposit Disease and C3 GN
- (2012) L. C. Herlitz et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
- (2012) Julien Zuber et al. Nature Reviews Nephrology
- Tailored Eculizumab Therapy in the Management of Complement Factor H–Mediated Atypical Hemolytic Uremic Syndrome in an Adult Kidney Transplant Recipient: A Case Report
- (2012) L. Xie et al. TRANSPLANTATION PROCEEDINGS
- Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases
- (2011) M. Fridkis-Hareli et al. BLOOD
- Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival
- (2011) R. J. Kelly et al. BLOOD
- Pre-emptive Eculizumab and Plasmapheresis for Renal Transplant in Atypical Hemolytic Uremic Syndrome
- (2011) C. Nester et al. Clinical Journal of the American Society of Nephrology
- Molecular Intercommunication between the Complement and Coagulation Systems
- (2010) U. Amara et al. JOURNAL OF IMMUNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started